Erola JA. We need dialogue and discussion, not a new Berlin Wall. CMAJ.1994;150:955-956.
Guyatt G. Academic medicine and the pharmaceutical industry. CMAJ.1994;150:951-953.
Waud DR. Pharmaceutical promotions—a free lunch? N Engl J Med.1992;327:351-353.
Woollard RF. Addressing the pharmaceutical industry's influence on professional
Wolfe SM. Why do American drug companies spend more than $12 billion a year pushing
drugs? J Gen Intern Med.1996;11:637-639.
Woosley RL. Centers for education and research in therapeutics. Clin Pharmacol Ther.1994;55:249.
Drake D, Uhlman M. Making Medicine, Making Money. Kansas City, Mo: Andrews & McMeel; 1993.
Randall T. Kennedy hearings say no more free lunch—or much else—from
drug firms. JAMA.1991;265:440, 442.
Palmisano P, Edelstein J. Teaching drug promotion abuses to health profession students. J Med Educ.1980;55:453-455.
Hemminki E. Review of literature on the factors affecting drug prescribing. Soc Sci Med.1975;9:111-116.
Smith MC. Drug product advertising and prescribing. Am J Hosp Pharm.1977;34:1208-1224.
Lexchin J. Interactions between physicians and the pharmaceutical industry. CMAJ.1993;149:1401-1407.
Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company
funding of continuing medical education. J Contin Educ Health Prof.1988;8:13-20.
Spingarn RW, Berlin JA, Strom BL. When pharmaceutical manufacturers' employees present grand rounds,
what do residents remember? Acad Med.1996;71:86-88.
Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing
Chren MM, Landefeld CS. Physicians' behavior and their interactions with drug companies. JAMA.1994;271:684-689.
Bowman MA. The impact of drug company funding on the content of continuing medical
Gibbons RV, Landry FJ, Blouch DL.
et al. A comparison of physicians' and patients' attitudes toward pharmaceutical
industry gifts. J Gen Intern Med.1998;13:151-154.
Sandberg WS, Carlos R, Sandberg EH, Roizen MF. The effect of educational gifts from pharmaceutical firms on medical
students' recall of company names or products. Acad Med.1997;72:916-918.
Mahood S, Zagozeski C, Bradel T, Lawrence K. Pharmaceutical policies in Canadian family medicine training. Can Fam Physician.1997;43:1947-1951.
Hopper JA, Speece MW, Musial JL. Effects of an educational intervention on residents' knowledge and
attitudes toward interactions with pharmaceutical representatives. J Gen Intern Med.1997;12:639-642.
Sergeant MD, Hodgetts PG, Godwin M, Walker DM, McHenry P. Interactions with the pharmaceutical industry. CMAJ.1996;155:1243-1248.
Caudill TS, Johnson MS, Rich EC, McKinney WP. Physicians, pharmaceutical sales representatives and the cost of prescribing. Arch Fam Med.1996;5:201-206.
Strang D, Gagnon M, Molloy W.
et al. National survey of the attitudes of Canadian physicians towards drug-detailing
by pharmaceutical representatives. Ann R Coll Physicians Surg Can.1996;29:474-478.
Hodges B. Interactions with the pharmaceutical industry. CMAJ.1995;153:553-559.
Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA.1995;273:1296-1298.
Andaleeb SS, Tallman RF. Physician's attitudes toward pharmaceutical sales representatives. Health Care Manage Rev.1995;20:68-76.
Poirier TI, Giannetti V, Giudici RA. Pharmacists' and physicians' attitudes toward pharmaceutical marketing
practices. Am J Hosp Pharm.1994;51:378-381.
Thomson AN, Craig BJ, Barham PM. Attitudes of general practitioners in New Zealand to pharmaceutical
representatives. Br J Gen Pract.1994;44:220.
Brotzman GL, Mark DH. The effect on resident attitudes of regulatory policies regarding pharmaceutical
representative activities. J Gen Intern Med.1993;8:130-134.
Reeder M, Dougherty J, White LJ. Pharmaceutical representatives and emergency medicine residents. Ann Emerg Med.1993;22:105-108.
Keim SM, Sanders AB, Witzke DB, Dyne P, Fulginiti JW. Beliefs and practices of emergency medicine faculty and residents regarding
interactions with the biomedical industry. Ann Emerg Med.1993;22:1576.
Banks III JW, Mainous III AG. Attitudes of medical school faculty toward gifts from the pharmaceutical
industry. Acad Med.1992;67:610-612.
Brotzman GL, Mark DH. Policies regulating the activities of pharmaceutical representatives
in residency programs. J Fam Pract.1992;1:54-57.
Bucci KK, Frey KA. Involvement of pharmacy faculty in the development of policies for
pharmaceutical sales representatives. J Fam Pract.1992;34:49-52.
Lichstein PR, Turner RC, O'Brien K. Impact of pharmaceutical company representatives on internal medicine
residency programs. Arch Intern Med.1992;152:1009-1013.
McKinney WP, Schiedermayer DL, Lurie N, Simpson DE, Goodman JL, Rich EC. Attitudes of internal medicine faculty and residents toward professional
interaction with pharmaceutical sales representatives. JAMA.1990;264:1693-1697.
Lurie N, Rich EC, Simpson DE.
et al. Pharmaceutical representatives in academic medical centers. J Gen Intern Med.1990;5:240-243.
Peay MY, Peay ER. The role of commercial sources in the adoption of a new drug. Soc Sci Med.1988;26:1183-1189.
Bower AD, Burkett GL. Family physicians and generic drugs. J Fam Pract.1987;24:612-616.
Haayer F. Rational prescribing and sources of information. Soc Sci Med.1982;16:2017-2023.
Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonist. N Engl J Med.1998;338:101-106.
Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern Med.1996;124:485-489.
Rochon PA, Gurwitz JH, Simms RW.
et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory
drugs in the treatment of arthritis. Arch Intern Med.1994;154:157-163.
Anderson JJ, Felson DT, Meenan RF. Secular changes in published clinical trials of second-line agents
in rheumatoid arthritis. Arthritis Rheum.1991;34:1304-1309.
Davidson RA. Source of funding and outcome of clinical trials. J Gen Intern Med.1986;1:155-158.
Hill AB. The environment and disease. Proc R Soc Med.1965;58:295-300.
Landefeld CS, Chren MM. Drug companies and information about drugs: recommendations for doctors. J Gen Intern Med.1996;11:642-644.
Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing
behavior of physicians. Am J Med.1982;73:4-8.
Hemminki E. Content analysis of drug-detailing by pharmaceutical representatives. Med Educ.1977;11:210-215.
Wade VA, Mansfield PR, McDonald PJ. Drug companies' evidence to justify advertising. Lancet.1989;2:1261-1263.
Canadian Medical Association. Physicians and the pharmaceutical industry (update 1994). CMAJ.1994;150:256A-256F.
Council on Ethical and Judicial Affairs, American Medical Association. Gifts to physicians from industry. JAMA.1991;265:501.
Guidelines for faculty involvement in commercially supported continuing
medical education. Acad Med.1992;67:615-621.
American College of Physicians. Physicians and the pharmaceutical industry. Ann Intern Med.1990;112:624-626.
Bickell NA. Drug companies and continuing medical education. J Gen Intern Med.1995;10:392-394.
Anastasio GD, Little JM. Pharmaceutical marketing. Pharmacotherapy.1996;16:103-107.
Daniel EE, Leedham L. Effect on student attitudes of a program of critical evaluation of
claims for drugs. J Med Educ.1966;41:49-60.
Ferguson RP. Training the resident to meet the detail men. JAMA.1989;261:992-993.
Shear NH, Black F, Lexchin J. Examining the physician-detailer interaction. Can J Clin Pharmacol.1996;3:175-179.
Berings D, Blondeel L, Habraken H. The effect of industry-independent drug information on the prescribing
of benzodiazepines in general practice. Eur J Clin Pharmacol.1994;46:501-505.
Soumerai SB, McLaughlin TJ, Avorn J. Improving drug prescribing in primary care. Milbank Q.1989;67:268-317.